Carmen Sarries

Learn More
BACKGROUND Platinum-based doublets are the standard chemotherapy for advanced non-small-cell lung cancer (NSCLC). Excision-repair cross-complementing 1 (ERCC1), xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) are essential to the repair of cisplatin DNA adducts. Multidrug resistance 1 (MDR1) has been related to(More)
PURPOSE Genetic analysis has shown that cell-free circulating DNA in plasma or serum of cancer patients shares similar genetic alterations to those described in the corresponding tumor. One of the most important alterations involved in carcinogenesis is aberrant promoter methylation. The interest in this field has grown due to the implementation of the(More)
Only about one third of non-small-cell lung cancer (NSCLC) patients respond to cisplatin-based chemotherapy. Cisplatin DNA adducts are commonly repaired through the nucleotide excision repair pathway. The study of rare inherited disorders such as xeroderma pigmentosum and Cockayne syndrome has disclosed that XP genes, including XPD, play an essential role(More)
7031 Background: We assessed SNPs in five DNA repair genes belonging to three of the major DNA repair pathways: XRCC1 Arg399Gln, XRCC3 Thr241Met, XPD Asp312Asn, XPD Lys751Gln, ERCC1 C118T, and RRM1 -37C/A and correlated the results with outcome in gem/cis-treated NSCLC p. METHODS 135 stage IV NSCLC p were included from August 2001 to July 2002. TaqMan 5'(More)
  • 1